Skip to main navigation
Skip to search
Skip to main content
Experts@Minnesota Home
Home
Profiles
Research units
University Assets
Projects and Grants
Research output
Press/Media
Datasets
Activities
Fellowships, Honors, and Prizes
Search by expertise, name or affiliation
Abiraterone acetate: CYP17 inhibitor oncolytic
S. Shah,
C. J. Ryan
Research output
:
Contribution to journal
›
Review article
›
peer-review
8
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Abiraterone acetate: CYP17 inhibitor oncolytic'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Androgen Receptor
100%
Abiraterone Acetate
100%
Oncolytic
100%
CYP17 Inhibitor
100%
Castration-resistant Prostate Cancer
66%
Adrenal Androgens
66%
Phase II Trial
33%
Therapeutic Target
33%
Phase I Trial
33%
Standard of Care
33%
Androgen Deprivation Therapy
33%
Androgens
33%
Phase III Clinical Trial
33%
Orally Administered
33%
Testosterone
33%
Progressive Disease
33%
Advanced Prostate Cancer
33%
Receptor-mediated
33%
Castration
33%
Prostate-specific Antigen
33%
Mediated Growth
33%
Toxicity Profile
33%
Extragonadal
33%
Specific Inhibitor
33%
Accruals
33%
Misnomer
33%
Androgen Biosynthesis
33%
CYP17A1
33%
Secondary Hormonal Therapy
33%
Rate-limiting Enzyme
33%
Hormone-sensitive Prostate Cancer
33%
Medicine and Dentistry
Androgen Receptor
100%
Castration Resistant Prostate Cancer
100%
Cytochrome P450 Family 17
100%
Abiraterone Acetate
100%
Androgen
100%
Disease
33%
Prostate Cancer
33%
Clinical Trial
33%
Androgen Deprivation Therapy
33%
Phase I Trials
33%
Phase II Trials
33%
Progressive Disease
33%
Hormone Therapy
33%
Prostate Specific Antigen
33%
Androgen Synthesis
33%
CYP17A1
33%
Pharmacology, Toxicology and Pharmaceutical Science
Abiraterone Acetate
100%
Cytochrome P450 Family 17
100%
Androgen
100%
Androgen Receptor
60%
Castration Resistant Prostate Cancer
60%
Disease
40%
Phase II Trials
20%
Clinical Trial
20%
Phase I Trials
20%
Hormone Cancer Therapy
20%
Prostate Cancer
20%
Prostate Specific Antigen
20%
CYP17A1
20%